Globus Medical (NYSE:GMED) Rating Lowered to “Hold” at Zacks Research

Globus Medical (NYSE:GMED) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Several other analysts have also recently commented on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Wells Fargo & Company decreased their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Royal Bank Of Canada raised their price objective on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, Needham & Company LLC boosted their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $105.00.

Globus Medical Stock Performance

Globus Medical stock opened at $78.90 on Monday. Globus Medical has a one year low of $51.79 and a one year high of $101.40. The company has a 50-day simple moving average of $81.48 and a 200-day simple moving average of $87.04. The firm has a market capitalization of $10.71 billion, a P/E ratio of 18.35, a P/E/G ratio of 1.66 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same period in the previous year, the business posted $0.68 EPS. Globus Medical’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts forecast that Globus Medical will post 4.74 earnings per share for the current year.

Insider Activity

In related news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director directly owned 510,175 shares in the company, valued at $41,201,733. The trade was a 4.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 18.38% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GMED. Annex Advisory Services LLC acquired a new stake in shares of Globus Medical during the fourth quarter worth $20,572,000. Kingdon Capital Management L.L.C. increased its stake in Globus Medical by 51.6% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 257,650 shares of the medical device company’s stock worth $14,756,000 after purchasing an additional 87,650 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in Globus Medical by 44.6% during the 3rd quarter. Kennedy Capital Management LLC now owns 490,949 shares of the medical device company’s stock worth $28,117,000 after buying an additional 151,500 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in Globus Medical by 71,618.6% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company’s stock worth $62,555,000 after buying an additional 715,470 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in Globus Medical by 510.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 266,532 shares of the medical device company’s stock valued at $23,271,000 after buying an additional 222,841 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.